Govt mulling ban on sale of TB drugs in open market

The Health Ministry is proposing changes in view of irregularity in administration of these drugs to patients

Press Trust of India New Delhi
Last Updated : Jul 04 2013 | 4:38 PM IST
Sale of tuberculosis drugs could be prohibited in open market as part of efforts to ensure calibrated and monitored administration of these medicines which would then only be given on daily basis free of cost by government registered outlets to patients.

The Health Ministry is proposing changes in view of irregularity in administration of these drugs to patients and lack of proper monitoring which is hindering efforts to check the disease, sources told PTI.

According to a WHO estimate, India is home to the largest number of TB patients- 2.2 million of the world's 8.7 million.

Also Read

Patients are administered TB medicines either through government-run hospitals and clinics free of cost or by private practitioners.

According to the Health Ministry, about 65% of the TB patients avail these drugs under the government's DOT (Daily Observed Therapy) System while the rest opt for treatment by private practitioners and buy drugs from the chemists based on their prescription.

The latter results in irregularity of treatment which leads to relapse of the ailment as there is lack of proper monitoring, the sources said citing experts.

To address this, the government is planning to prohibit sale of drugs in open market.

Under the new initiative, patients going to private practitioners for treatment will get medicines free of cost from chemists but only after the doctor informs them through a dedicated call centre to be set up by the government.

The changes are being brought to ensure that all TB patients are administered the drugs on daily basis instead of intermittently as at present.

Recently, Health Minister Gulam Nabi Azad had expressed concern on the issue saying that the irregular regime is leading to growing resistance to anti-TB drugs.

The Health Ministry officials recently had held a meeting with WHO and other experts who had emphasised on changing intermittent dosage system to daily regime.

During the meeting, it was informed that many other countries including Brazil, China, which were following the intermittent dosage system, have now turned to daily regime.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 04 2013 | 4:37 PM IST

Next Story